LOS ANGELES, CA – CureSHANK will award a total of $250,000 aimed at stimulating research on SHANK3-related epilepsy, prevalent in Phelan-McDermid syndrome patients. The grants, CureSHANK Research to Cure Grant: Epilepsy (R2C Epilepsy), will provide targeted funding to support SHANK3-related epilepsy research projects. The awards aim to improve mechanistic and...
research News
Cambridge, UK – Whole genome sequencing has improved clinical care of some children with cancer in England by informing individual patient care. New research from the Wellcome Sanger Institute, Cambridge University Hospitals NHS Trust, Great Ormond Street Hospital, and the University of Cambridge, supports the efforts to provide genome sequencing...
GAINESVILLE, Fla. — Cyclo Therapeutics, Inc., a clinical stage biotechnology company focused on developing transformative therapies for rare and neurological diseases with limited treatment options, today announced a positive outcome from its recent Type C meeting with the U.S. Food and Drug Administration (FDA) to discuss a full data review...
NEWARK, Calif. — CymaBay Therapeutics, Inc., a biopharmaceutical company focused on innovative therapies for patients with liver and other chronic diseases, today announced it has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for investigational treatment, seladelpar, for the management of primary biliary cholangitis,...
The inherited progressive disorder cystic fibrosis (CF) causes severe damage to the lungs, and other tissues in the body by affecting the cells that produce mucus, sweat, and digestive juices. In individuals carrying mutations in the cystic fibrosis transmembrane conductance regulator (CFTR) gene, which encodes an ion channel controlling the...
BETHESDA, Md. — The Cystic Fibrosis Foundation announced that it will provide up to $15 million to Prime Medicine for preclinical research into gene editing for cystic fibrosis. Prime Medicine is using a gene editing technology called prime editing — a technology that enables insertions or deletions of small segments of...
VANCOUVER, Wash. — CytoDyn Inc. (OTCQB: CYDY), a biotechnology company developing leronlimab, a CCR5 antagonist with the potential for multiple therapeutic indications, announced today that the Company has submitted its revised HIV clinical trial protocol to the FDA. The Company believes this submission will lead to the removal of the...
Sydney, Australia – In good news for office workers, a new study from the University of Sydney’s Charles Perkins Centre has found increasing your step count may counteract the health consequences of too much sedentary time each day. The study of over 72,000 people, published in the British Journal of...
Boston, MA — Researchers at Dana-Farber Cancer Institute have developed a blood test that could transform the diagnosis and monitoring of multiple myeloma (MM) and its precursor conditions. The new method, known as SWIFT-seq, utilizes single-cell sequencing to profile circulating tumor cells (CTCs) in the blood, offering a non-invasive alternative to traditional...
Boston, Mass. – Researchers at Dana-Farber Cancer Institute have created a CRISPR-based rapid molecular diagnostic for two forms of leukemia that are driven by mutations that involve gene fusions. The technology accurately detects the presence of these gene fusions in acute promyelocytic leukemia (APL) and chronic myeloid leukemia (CML) in...